The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Suzhou Abogen Biosciences
Preliminary safety, antitumor activity, and pharmacodynamics of intratumoral ABO2011 (IL-12 mRNA) in patients with advanced solid tumors.
 
Ning Li
Research Funding - Boehringer Ingelheim (Inst); Cullgen (Inst); Lyvgen Biopharma (Inst); Suzhou Abogen Biosciences (Inst); TCRCure Biopharma (Inst)
 
Ning Li
Research Funding - Suzhou Abogen Biosciences (Inst)
 
Yong Wang
Research Funding - Suzhou Abogen Biosciences (Inst)
 
Ningyi Cui
Research Funding - Suzhou Abogen Biosciences (Inst)
 
Xin Wang
Research Funding - Suzhou Abogen Biosciences (Inst)
 
Yu Tang
Research Funding - Suzhou Abogen Biosciences (Inst)
 
Yuting Chu
Employment - Suzhou Abogen Biosciences
 
Qingwei Meng
Employment - Suzhou Abogen Biosciences
 
Rui Lin
Employment - Suzhou Abogen Biosciences
 
Yan Wu
No Relationships to Disclose
 
Bo Ying
Employment - Suzhou Abogen Biosciences
Leadership - Suzhou Abogen Biosciences
Stock and Other Ownership Interests - Suzhou Abogen Biosciences
Honoraria - Suzhou Abogen Biosciences
Research Funding - Suzhou Abogen Biosciences (Inst)
Travel, Accommodations, Expenses - Suzhou Abogen Biosciences